Home › Research › Biomarkers
Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects
Wong DF, Comley RA, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, Vozzi C, Boess F et al.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018-05-04
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
In younger controls, SUV peak was observed in the temporal lobe with values of approximately 3.0 for 11 C-RO-963, 1.5 for 11 C-RO-643, and 3.5 for 18 F-RO-948. Over all brain regions and subjects, the trend was for 18 F-RO-948 to have the highest SUV peak , followed by 11 C-RO-963 and then 11 C-RO-643. Regional analysis of SUV ratio and total distribution volume for 11 C-RO-643 and 18 F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that 11 C-RO-643 had lower brain entry than either 11 C-RO-963 or 18 F-RO-948 and that 18 F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on 18 F-RO-948. Both voxelwise and region-based analysis of 18 F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA, F (1,21) = 45, P -5 ). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of P 50). 18 F-RO-948 demonstrates characteristics superior to 11 C-RO-643 and 11 C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of 18 F-RO-948 compare favorably with other existing tau PET tracers.
What this study adds
Evidence grade: Low
This study characterized three tau radiopharmaceuticals and found that 18F-RO-948 showed better contrast between areas of high and low tau accumulation and could distinguish Alzheimer's disease subjects from healthy controls. It is a diagnostic imaging study and does not report any treatment, cure, or prevention of Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wong, D. F., Comley, R. A., Kuwabara, H., Rosenberg, P. B., Resnick, S. M., Ostrowitzki, S., et al. (2018). Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. https://doi.org/10.2967/jnumed.118.209916
Vancouver
Wong DF, Comley RA, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, et al. Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018. doi:10.2967/jnumed.118.209916. PMID: 29728519.
BibTeX
@article{wong2018-29728519,
author = {Wong, D. F. and Comley, R. A. and Kuwabara, H. and Rosenberg, P. B. and Resnick, S. M. and Ostrowitzki, S. and Vozzi, C. and Boess, F. and others},
title = {{Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects}},
journal = {Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
year = {2018},
doi = {10.2967/jnumed.118.209916},
pmid = {29728519},
url = {https://doi.org/10.2967/jnumed.118.209916}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In younger controls, SUV peak was observed in the temporal lobe with values of approximately 3.0 for 11 C-RO-963, 1.5 for 11 C-RO-643, and 3.5 for 18 F-RO-948.
- Over all brain regions and subjects, the trend was for 18 F-RO-948 to have the highest SUV peak , followed by 11 C-RO-963 and then 11 C-RO-643.
- Regional analysis of SUV ratio and total distribution volume for 11 C-RO-643 and 18 F-RO-948 clearly discriminated the AD group from the healthy control groups.
- Compartmental modeling confirmed that 11 C-RO-643 had lower brain entry than either 11 C-RO-963 or 18 F-RO-948 and that 18 F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation.
- Thus, our subsequent analysis focused on 18 F-RO-948.
Why it matters
This study characterized three tau radiopharmaceuticals and found that 18F-RO-948 showed better contrast between areas of high and low tau accumulation and could distinguish Alzheimer's disease subjects from healthy controls. It is a diagnostic imaging study and does not report any treatment, cure, or prevention of Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of nuclear medicine : official publication, Society of Nuclear Medicine) |
| Journal's citation record | 2 / 4 | Journal of Nuclear Medicine: journal h-index 230 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 104 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.4 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 4 / 6 | Cited 9.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 9 other studies in this library |
| Still being cited | 2 / 4 | Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Edilio Borroni: h-index 43 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | National Institutes of Health: institution h-index 2,723 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29728519) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.